文献速递前列腺癌

转移性去势敏感性前列腺癌中Medicare受益人与退伍军人之间新出现的种族差异

Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-04-02

该研究评估了Medicare(2015-2018)和退伍军人健康管理局(VHA;2015-2019)转移性去势敏感性前列腺癌(mCSPC)患者的治疗强化(TI)和总生存(OS)。结果显示,黑人与白人患者相比,Medicare中TI显著更低(调整OR 0.68;95%CI 0.58-0.81),OS更差(调整HR 1.20;95%CI 1.09-1.31);VHA中TI也显著更低(调整OR 0.75;95%CI 0.61-0.92),但OS无显著差异。医疗补助患者无论种族TI均较少且OS更差。

要点

  • Medicare中黑人mCSPC患者治疗强化显著低于白人(调整OR 0.68;95%CI 0.58-0.81),OS更差(调整HR 1.20;95%CI 1.09-1.31)。
  • VHA中黑人患者治疗强化也显著更低(调整OR 0.75;95%CI 0.61-0.92),但OS无显著种族差异。
  • 医疗补助患者无论种族治疗强化均较少且OS更差,提示贫困与种族均与诊疗和结局相关。

核心结论

  • 指南推荐的治疗强化在所有mCSPC患者中均较低,黑人在Medicare和VHA中均接受更少的治疗强化。
  • 黑人种族在Medicare中与更差OS相关,但在VHA中无显著OS差异。
  • 医疗补助患者比无医疗补助者治疗强化更少且OS更差,提示贫困和种族与诊疗及结局相关。

研究设计与样本

  • 研究评估了Medicare(2015-2018)和VHA(2015-2019)mCSPC患者的治疗强化和总生存。
  • 分析纳入Medicare黑人2226例、白人16071例,VHA黑人1020例、白人2364例。
  • 一线mCSPC治疗分类为:雄激素剥夺治疗(ADT)+新型激素治疗;ADT+多西他赛;ADT+第一代非甾体抗雄激素;或单用ADT。

主要发现

  • Medicare中黑人vs白人总体治疗强化调整OR 0.68(95%CI 0.58-0.81),无医疗补助者调整OR 0.70(95%CI 0.57-0.87)。
  • Medicare中黑人vs白人总体OS调整HR 1.20(95%CI 1.09-1.31),无医疗补助者调整HR 1.13(95%CI 1.01-1.27)。
  • 医疗补助患者比无医疗补助者OS更差,但种族间OS无显著差异。
  • VHA中黑人vs白人治疗强化调整OR 0.75(95%CI 0.61-0.92),种族间OS无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have shown that Black men receive worse prostate cancer care than White men. This has not been explored in metastatic castration-sensitive prostate cancer (mCSPC) in the current treatment era. METHODS: We evaluated treatment intensification (TI) and overall survival (OS) in Medicare (2015-2018) and Veterans Health Administration (VHA; 2015-2019) patients with mCSPC, classifying first-line mCSPC treatment as androgen deprivation therapy (ADT) + novel hormonal therapy; ADT + docetaxel; ADT + first-generation nonsteroidal antiandrogen; or ADT alone. RESULTS: We analyzed 2226 Black and 16,071 White Medicare, and 1020 Black and 2364 White VHA patients. TI was significantly lower for Black vs White Medicare patients overall (adjusted odds ratio [OR] 0.68; 95% confidence interval [CI] 0.58-0.81) and without Medicaid (adjusted OR 0.70; 95% CI 0.57-0.87). Medicaid patients had less TI irrespective of race. OS was worse for Black vs White Medicare patients overall (adjusted hazard ratio [HR] 1.20; 95% CI 1.09-1.31) and without Medicaid (adjusted HR 1.13; 95% CI 1.01-1.27). OS was worse in Medicaid vs without Medicaid, with no significant OS difference between races. TI was significantly lower for Black vs White VHA patients (adjusted OR 0.75; 95% CI 0.61-0.92), with no significant OS difference between races. CONCLUSIONS: Guideline-recommended TI was low for all patients with mCSPC, with less TI in Black patients in both Medicare and the VHA. Black race was associated with worse OS in Medicare but not the VHA. Medicaid patients had less TI and worse OS than those without Medicaid, suggesting poverty and race are associated with care and outcomes.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. George DJ, Agarwal N, Ramaswamy K, et al. Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38565911. doi:10.1038/s41391-024-00815-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。